## Medication Errors

Dr. Mohammed Abuelkhair Ex-Director of Pharmaceutical and Medical Device Regulation Department of Health-Abudhabi

# Epidemiology

- Interesting but horrifying fact-
  - More people in USA die in a given year as a result of medical errors than from motor vehicle accidents, breast cancers, or AIDS
- Majority are <u>medication errors</u>
- Indian study of paediatric intensive care unit reported 68.5% of all errors were medication errors

## Classification



### WHICH PATIENTS ARE MOST AT RISK OF MEDICATION ERROR?

- Patients on multiple medications
- Patients with another condition, e.g. renal impairment, pregnancy
- Patients who cannot communicate well
- Patients who have more than one doctor
- Patients who do not take an active role in their own medication use
- Children and babies (dose calculations required)



- Errors occur from-
  - Lack of knowledge
  - Unclear or erroneous labeling of drug
  - Misidentification of patient
  - Mental lapses or
  - Verification errors

• Errors committed by both experienced & inexperienced staff

#### Sources of Errors

Incorrect transcription (e.g. from verbal to written or paper to digital format)	Mix-up of patients (e.g. distractions and interruptions during drug administration)	k-up of patients distractions and erruptions during g administration) Mix-up of drugs (e.g. lack of light on a night shift, similar drug names and packaging) Mistakes in calculation of drug concentration						
Use of inappropriate diluents				Wrong / omitted / passed expiry date				
Contamination of solutions		Medication Error		Difficulties in handling certain IV preparation techniques				
Wrong storage				small vials for a single administration)				
Insuffi cient mixing of ingredients (e.g. insufficient dissolution of drug powders)	Incompatibilities (e.g. due to diff erence in pH)	Adsorption (container / IV sets)	Incorrect infusion rate	Incomplete delivery of the container contents <sub>9</sub>				

## Drug Compatibility

Compatible (at Y-site only)
-----------------------------

Numbers below refer to references. Symbols are explained immediately below the table.

	Aminophylline pH 8.8-10.0	Caffeine pH 2.0-3.0	Dobutamine pH 2.5-5.5	Dopamine pH 2.5-4.5	Fentanyl pH 4.0-7.55	Heparin pH 5.5-8.0	Indomethacin pH 6.0-7.5	Norphine pH 2.5-6.0	Prostaglandin E1	NaHCO₃ pH 7.0-8.5	NN pH 5.5-6.5	Intralipid pH 5.5
Aminophylline pH 8.8-10.0		?	<b>X</b> 1	√ 1	?	√ +++ 1	?	√ 12	√ ++ 10 +	?	<b>X</b> 21	<b>X</b> 13
Caffeine pH 2.0-3.0	?		?	?	?	?	<b>X</b> 2	?	?	?	X 4	x
Dobutamine pH 2.5-5.5	<b>X</b> 1	?		√ 1	?	?	<b>X</b> 11	√ 5	?	<b>X</b> 1	√ 20	?
Dopamine pH 2.5-4.5	√ 1	?	1		?	√ 1	<b>X</b> 11	√ 1	√ +10	<b>X</b> 1,3	√ 20	?
Fentanyl pH 4.0-7.55	?	?	?	?		√ 1	?	?	?	?	√ 20	?
Heparin pH 5.5-8.0	√ +++1	?	?	√ 1	√ 1		?	√ *6	√ +10	?	?	√ #1
Indomethacin pH 6.0-7.5	?	<b>X</b> 2	<b>X</b> 11	<b>X</b> 11	?	?		<b>X</b> 8,9	?	<b>X</b> 11	<b>X</b> 11	<b>X</b> 8,9
Morphine pH 2.5-6.0	√ 12	?	√ 5	<b>√</b> 1	?	√ *6	<b>X</b> 8,9		√ +10	√ 1, 18	√ 20	<b>?</b> **15
Prostaglandin E1	√ ++ 10+	?	?	√ +10	?	√ +10	?	√ +10		?	?	<b>X</b> 7
NaHCO3 pH 7.0-8.5	?	?	<b>X</b> 1	<b>X</b> 1,3	?	?	<b>X</b> 11	√ 1, 18	?		?	x
NN pH 5.5-6.5	<b>X</b> 21	<b>X</b> 4	√ 20	√ 20	√ 20	?	<b>X</b> 11	√ 20	?	?		?
Intralipid pH 5.5	<b>X</b> 13	X	?	?	?	√ #i	<b>X</b> 8,9	<b>?</b> **15	<b>X</b> 7	x	?	

### Drug Shortages Cause Treatment Delays

- Missed opportunities to immunize
- Delays for antimicrobials may be life-threatening
- Clinical trial enrollment delays standard of care not available
- Treatment delays survey of oncology practitioners in US – 83% say drug of choice not available, 75% had to switch patients to a potentially less effective agent.

J Natl Cancer Inst. 2012;104(12):891-892 AJHP. 2013;70(7):609-617

Clin Infect Dis. 2012;54(5):684-691 NEJM 2013;369(25):2463-2464

#### Drug Shortages Cause Adverse Patient Outcomes

Zinc shortage results in dermatitis for premature infants. Children's National Hospital, United States



hoto/S.A. Norton, Children's National Medical Center

http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6207a5.htm

### Case #1

LF is a 63 yom with a h/o asthma, DM, HTN, HLD, and PVD who presents with unstable angina and is going to go for PCI with probable stent placement. He started on antiplatelet before the PCI and was discharged without antiplatelet.

The patient died after 1 week of discharge

#### HOW CAN PRESCRIBING GO WRONG?

- Inadequate knowledge about drug indications and contraindications
- Not considering individual patient factors, such as allergies, pregnancy, co-morbidities, other medications
- Wrong patient, wrong dose, wrong time, wrong drug, wrong route
- Inadequate communication (written, verbal)
- Documentation illegible, incomplete, ambiguous
- Mathematical error when calculating dosage
- Incorrect data entry when using computerized prescribing e.g. duplication, omission, wrong number

## Dispensing errors

- Receipt of the prescription supply of a dispensed medicine to patient
- Occurs primarily with drugs having similar name or appearance
- Example :lasix® (frusemide) and losec®(omeprazole)
- Other potential dispensing errors include
  - wrong dose P
  - wrong drug M
  - wrong patient



At the Impatient Pharmacy



### HOW CAN ADMINISTRATION GO WRONG?

- Wrong patient
- Wrong route
- Wrong time
- Wrong dose
- Wrong drug
- Omission, failure to administer
- Inadequate documentation

### "POINT OF USE" LABEL



#### IV Compound Bag Label



#### Compound Label for Syringe







#### IN WHAT SITUATIONS ARE STAFF MOST LIKELY TO CONTRIBUTE TO A MEDICATION ERROR?

- Inexperience
- Rushing, doing two things at once
- Interruptions
- Fatigue, boredom, being on "automatic pilot" leading to failure to check and double-check
- Lack of checking and double checking (including two-person checking) habits
- Poor teamwork and/or communication between colleagues
- Reluctance to use memory aids

### Anaphylaxis

- Acute, life-threatening allergic reactions involving multiple organ systems
  - Dermatologic
  - Respiratory
  - Gastrointestinal
  - Cardiovascular
- Accounts for 1500 deaths per year in the US
- Occurs within 30 minutes of exposure
- Monitor for late phase reaction for 12 hours

#### Case #2

AP is a 72 yof with a history of Chronic Fatigue, CHF, HTN and Fibromylagia. Her medication allergies include asprin allergy. When asked she says it causes rash.

The ER physician gave her Ketrolac IV, she was discharged and after 45 minutes she had passed away.

Table 2

#### Commonly Used NSAIDs by Chemical Structure

Chemical Class	Medications	Comments
Salicylic acid derivatives	Aspirin	Strong COX-1 inhibition
Propionic acid derivatives	lbuprofen, naproxen, ketoprofen, oxaprozin	Strong COX-1 inhibition
Acetic acid derivatives	Indomethacin, sulindac, etodolac, ketorolac, diclofenac, nabumetone	Strong COX-1 inhibition
Para-aminophenol derivatives	Acetaminophen	Weak COX-1 inhibition
Enolic acid derivatives	Meloxicam, piroxicam	COX-2 inhibition > COX-1 inhibition
Selective COX-2 inhibitors	Celecoxib	Highly selective COX-2 inhibition
COX-1: cyclooxygenase-1; COX-2: c	yclooxygenase-2; NSAID: nonsteroidal anti-infla	mmatory drug.

Source: Reference 2.

#### Chemical Classes of Opioids

PHENANTHRENES	BENZOMORPHANS	PHENYLPIPERIDINES	DIPHENYLHEPTANES	PHENYLPROPYL AMINES
HOLAN	HO		SC -	HO H CH3
MORPHINE	PENTAZOCINE	FENTANYL	METHADONE	TRAMADOL
Buprenorphine* Butorphanol* Codeine Destromethorphan* Dihydrocodeine Heroin (diacetyl-morphine) Hardines	Diphenoxylate Loperamide Pentazocine	Alfentanil Fentanyl Meperidine Remifentanil Sufentanil	Methadone Propoxyphene	Tapentadol Tramadol
Hydromorphone*		Illicit Fentanyl		
Levorphanor* Methylnaltrexone** Morphine (Opium, conc) Nalbuphine* Naloxegol* Naloxegol* Naltrexone** Oxycodone* Oxymorphone*		Furanyl fentanyl Acetyl fentanyl Fluoro-fentanyl Carfentanil		
201270302000-00-00-00		CROSS-SENSITIVITY RISH	¢.	- contract of the second
PROBABLE	POSSIBLE	LOW RISK	LOW RISK	LOW RISK

Jeffrey Fudin, BSPharm, PharmD, DAIPM, FCCP, FASHP, FFSMB

http://paindr.com/wp-content/uploads/2018/02/Opioid-Structural-Classes-Figure\_-updated-2018-02.pdf



Table 1. NSAID Selectivity									
More COX-1 Selective	Nonselective	5-50-fold COX-2 selective <sup>a</sup>	>50-fold COX-2 selective*						
Ketorolac (Sprix, others) Flurbiprofen Ketoprofen Indomethacin (Indocin, others) Aspirin Naproxen (Aleve, Naprosyn, others) Tolmetin Piroxicam (Feldene, others) Meclofenamate	Ibuprofen Fenoprofen <sup>∉</sup> Sodium salicylate Diflunisal	Sulindac Diclofenac Celecoxib (Celebrex) Meloxicam (Mobic, others)ª Etodolac	Valdecoxib <sup>a</sup> Etoricoxib <sup>a</sup> Rofecoxib <sup>a</sup> Lumiracoxib <sup>a</sup>						

COX, cyclo-oxygenase; FDA, Food and Drug Administration; NSAID, non-steroidal anti-inflammatory drug \*Listed in order of increasing COX-2 selectivity \*Withdrawn from US market \*Equipotent for COX-1 and COX-2 selectivity \*At higher doses, COX-2 selectivity decreases and COX-1 inhibition is stronger than COX-2 \*Not approved by the FDA

#### Case #2

- JT is a 56 yom with a history of DM, HTN, and HLD.
- He presents with MSSA bacteremia secondary to a diabetic foot infection. He has a history of penicillin allergy.

How would you manage his infection?

## Cephalosporins

- Cross-reactivity with penicillin allergy is up to 10%
  - Higher incidence with 1<sup>st</sup> generation cephalosporins
  - Patients with negative skin test are at no higher risk than general population

#### Management

- Positive skin test avoidance or desensitization
- Mild reaction to penicillin proceed with caution

#### Table 1: Penicillins and cephalosporins with similar side chains<sup>7</sup>

Cross reactions b	Similar C-7 Side Chain Cross reactions between agents within one group is possible											
Group 1	Group 2	Group 3										
Penicillin	Amoxicillin	Cefepime										
Cephalothin	Ampicillin	Ceftizoxime										
Cephalodrine	Cefaclor	Cefpirome										
Cefoxitin	Cephadrine	Cefotaxime										
	Cephalexin	Cefpodoxime										
	Cefadroxil	Ceftriaxone										
	Cefatrizine	Cefetamet										
		Cefeteram										

	Cefazolin (1º1)	Defactor (2 <sup>nd</sup> )	Cefadroxil (1*)	Cefamandole(2 <sup>rd</sup> )	Ceddinir (3 <sup>rg</sup> )	Cefepime (4 <sup>th</sup> )	Cefixime (3 <sup>rd</sup> )	Celoperazione (3 <sup>10</sup> )	Cefotaxime (3 <sup>rd</sup> )	Celotetan (2 <sup>nd</sup> )	Cefoxitin(2 <sup>md</sup> )	Celpiromo(4 <sup>th</sup> )	Cefpodoxime (3 <sup>14</sup> )	Cetprozii (2 <sup>n4</sup> )	Ceffazidime (3 <sup>10</sup> )	Ceftolozane (2nd)	Cettibuten (3 <sup>46</sup> )	Cofficacines (3 <sup>rd</sup> )	Ceftriaxone (3 <sup>rd</sup> )	Ceturoxime (2 <sup>nt</sup> )	Cephalexin (1 <sup>st</sup> )	Cephaloridine (1 <sup>4</sup> )	Cephradine (1º)	Celditoren (3º6)	Cettaroline (5 <sup>th</sup> )	Amoxiciliin	Ampicillin	Penicillin G	and a state of the
Cefazolin (1st)	-		Ģ				-		-		-	-	-			Ĩ	-			-	Ŭ	-		-	-	-	-	-	T
Cefacior (2 <sup>nd</sup> )		-	T	T			1							H							22		25			n	12		Г
Cefadroxil (1")		X	-	32										22							22		Ħ			11	25		Г
Cefamandole (2 <sup>rd</sup> )		22	H	-				21		M				Ħ		1		-			H		Ħ			Ħ	m		Г
Cefdinir (3 <sup>re</sup> )		_	-		-		21	r						_		1			1	1	-					-			t
Cefepime (4 <sup>th</sup> )						-	32		22			缸	32		It	H		x	22	H	[			12					195
Cefixime (3 <sup>rd</sup> )					n	H	-		X			u	H		32	Ħ		Ħ	Ħ	Ħ				H					4.6
Cefoperazone (3 <sup>rd</sup> )				I				-		I								-											Г
Cefotaxime (3 <sup>rd</sup> )						H	E		-	<b></b>		H	H		Ħ	H		10	22	H	1			H					-
Cefotetan(2 <sup>nd</sup> )				12				Ħ		-						1													ſ
Cefoxitin(2 <sup>nd</sup> )																1				R		H						3.5	Г
Cefpirome(4*)	1					12	IL	1	12			-	H		22	H		Ħ	Ħ	H				12					2.0
Cetpodoxime (3 <sup>d</sup> )						22	I		X			R	-		Ħ	Ħ		R	22	Ħ				22					2.4
Cefprozil(2 <sup>rd</sup> )		H	22	H										-	<b></b>						II		H			22	IL		Γ
Ceftazidime (3**)				-		R	II		Z			R	H			Ħ		I	II	H				H					5
Ceftolozane (2nd)	1					H	31		25			m	Ħ		X	•		Ħ	Ħ	Ħ				22					
Ceftibuten (3")																	-	21		<b></b>									Г
Ceffizoxime (3 <sup>rd</sup> )						12	H		12			12	-		H	Ħ	X	-	22	Ħ				22					2.4
Ceftriaxone (3 <sup>rd</sup> )						12	H		1			H	12		H	Ħ		21	F	2ª				-					24
Cefuroxime(2nd)	1					H	H		22		22	Ħ	Ħ		H	Ħ		R	H	-				Z					4.4
Cephalexin (1 <sup>st</sup> )		其	Ħ	Ħ										Ħ	$\square$						-		22			H	24		Γ
Cephaloridine (1*)											11							T		<b>—</b>		-						II.	Г
Cephradine (1 <sup>d</sup> )		22	22	Ħ										H							tt		-			Ħ	25		T
Cefditoren (3*)						12	II		11			I	R		H	Ħ		22	12	H	Ē			-				1	1
Cettaroline (5%)																									-				ſ
Amoxicillin		H	25	H										X							IL		II			-	J.		Γ
Ampicillin		-	20	21			1							200							22		31			31		-	1

Similar side chains	Penicillin	Amoxicillin	Ampicillin	Cephalexin	Cefuroxime	Cefoxitin	Ceftriaxone	Cefotaxime	Cefepime	Ceftazidime
Penicillin						Χ				
Amoxicillin			Х	X						
Ampicillin		X		Х						
Cephalexin		X	Χ							
Cefuroxime						Х	Χ	Χ		
Cefoxitin	Х				X					
Ceftriaxone					X			Х	Χ	Χ
Cefotaxime					X		X			Χ
Cefepime							X			
Ceftazidime							Χ	Χ		

### Carbapenems

■ Incidence of hypersensitivity 0.3-2.3%

#### Cross-reactivity

- Proven, suspected, or possible IgE mediated reaction to  $\beta$  lactams: 1.6 to 5.9%
- Proven IgE mediated reaction to β lactams: 0.5%
- Positive PCN skin test: 0.06 to 1.9%
- Negative PCN skin test: no reaction

#### Management

• In patients with proven IgE mediated reactions to β-lactams, consider graded challenge in ICU

Ann Pharmacother 2009;43:304-15. Clin Infect Dis 2014;59:1113-22.

#### Monobactams (Aztreonam)

No clinical cross-reactivity between βlactam antibiotics and aztreonam

#### Exceptions:

- Cystic fibrosis patients can develop sensitization reactions
- Ceftazidime shares similar structure, use in caution with ceftazidime allergy

# SULFONAMIDES

### Sulfonamide-Associated Reactions

- Anaphylaxis
- Angioedema
- Erythema multiforme
- Flushing
- Photosensitivity
- Pustular eruption
- Urticaria
- Bullous eruption
- Erythroderma
- Fixed drug eruption
- Lupus erythematosus
- Psoriasis
- Vasculitis

- Exanthema
- Aphthous stomatitis
- Erythema nodosum
- Exfoliative dermatitis
- Sweet's syndrome
- Pruritus
- Stevens-Johnson syndrome
- Toxic epidermal necrolysis
- Serum sickness
- Hepatitis
- Hemolytic anemia

#### Sulfonamides and Loop Diuretics



FIGURE 4. Sulfamethoxazole (SMX) molecule structure.



FIGURE 5. Furosemide molecule structure.

Journal of Hospital Medicine 2011;6(5):E1-E5.

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

#### Absence of Cross-Reactivity between Sulfonamide Antibiotics and Sulfonamide Nonantibiotics

Brian L. Strom, M.D., M.P.H., Rita Schinnar, M.P.A., Andrea J. Apter, M.D., David J. Margolis, M.D., Ph.D., Ebbing Lautenbach, M.D., M.P.H., M.S.C.E., Sean Hennessy, Pharm.D., Ph.D., Warren B. Bilker, Ph.D., and Dan Pettitt, D.V.M.

#### Cross-Reactivity of Sulfonamide Antibiotics and Nonantibiotics

#### Retrospective cohort study of 20,279 patients who received a sulfonamide antibiotic followed by a sulfonamide nonantibiotic within 60 days

Table 1. Sulfonamide Nonantibiotic Drugs.										
Acetazolamide	Cyclopenthiazide	Glyburide	Probenecid							
Acetohexamide	Dapsone	Glymidine	Quinethazone							
Bendroflumethiazide	Diazoxide	Hydrochlorothiazide	Sulfasalazine							
Benzthiazide	Dichlorphenamide	Hydroflumethiazide	Sulthiame							
Bumetanide	Furosemide	Indapamide	Tolazamide							
Chlorothiazide	Glibornuride	Mefruside	Tolbutamide							
Chlorpropamide	Gliclazide	Methyclothiazide	Torsemide							
Chlorthalidone	Glimepiride	Metolazone	Xipamide							
Clopamide	Glipizide	Piretanide								
Clorexolone	Gliquidone	Polythiazide								





#### Figure 1. Primary Analysis of a Cohort of Patients Who Had Received a Sulfonamide Antibiotic and Who Subsequently Received a Sulfonamide Nonantibiotic.

A narrow outcome was defined by the occurrence of reactions such as urticaria, anaphylactic shock, erythema multiforme, and drug allergy. A broad definition also included asthma, eczema, and unspecified adverse effects of a drug. For a complete list, see Supplementary Appendix 1, available with the full text of this article at http://www.nejm.org.

#### Cross-Reactivity of Sulfonamide Antibiotics and Nonantibiotics

- Most common reactions observed
  - Asthma (70.1%)
  - Eczema (14.1%)
  - Adverse drug reaction (11.4%)
- Is patients had symptoms consistent with type I hypersensitivity
- Previous reaction to a sulfonamide antibiotic was associated with a 2.8 times higher likelihood of having a reaction to the nonantibiotic
  - Similar risk was observed for patients with a sulfonamide allergy who received penicillin

#### Ethacrynic Acid

- Non-sulfa loop diuretic
- Approx. \$3000 per dose for IV
- 1:1 conversion from IV:PO
- Higher incidence of ototoxicity compared to other loop diuretics
- Reserve for patients with allergic reactions to loop diuretics